Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VX1.F | 095700.KQ | CSL.AX | KRYS | ROIV | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 118.89B | 111.88B | 94.12B | 9.52B | 27.43B | 33.76B |
| P/E (TTM) | 32.4 | — | — | 40.3 | — | 3.7 |
| Forward P/E | 35.8 | — | 20.6 | 35.9 | -22.1 | 10.0 |
| Price/book | 6.6 | — | 4.4 | 7.0 | 6.5 | 1.1 |
| Dividend yield | — | — | 2.07% | — | — | 1.75% |
| 1-year change | +23.34% | −51.15% | −11.16% | +72.79% | +103.09% | −47.31% |
| Today | +2.78% | −3.15% | +0.03% | −0.14% | +3.21% | −4.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VX1.F news ›AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established dividend payers and high-growth innovators is a classic investor dilemma. This comparison pits AbbVie (ABBV +2.26%) against Vertex Pharmaceuticals (VRTX +2.53%) to determine which company offers the best…
Vertex Pharmaceuticals (VRTX) Stock
Based on 9 analyst ratings The market is expecting earnings per share of $4.35 for this quarter. The company has not yet shared when it is announcing earnings. News tone: automated (AI) classification of the article's content, not a price…
Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?
Vertex is generating double-digit revenue growth, but with cystic fibrosis still contributing 96% of sales, its premium valuation puts the spotlight on diversification and future earnings. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)…
Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee
On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors of Vertex Pharmaceuticals Incorporated . In connection with the appointment of Mr. Brennan, the size of the... On October 20, 2026, Daniel Brennan…
Lobbying Update: $1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed
$1,100,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been…
3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Posted by Defense World Staff on Oct 17th, 2026 NASDAQ:VRTX opened at $499.74 on Friday. The stock’s fifty day moving average is $523.54 and its 200 day moving average is $480.55. Vertex Pharmaceuticals Incorporated has a fifty-two week…
How Vertex Pharmaceuticals Incorporated (VRTX) Affects Rotational Strategy Timing
Stock Traders Daily Key findings for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - Weak Near and Mid-Term Sentiment Could Challenge Long-Term Positive Outlook - Exceptional 25.9:1 risk-reward short setup targets 7.5% downside vs…
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653
www.marketscreener.com Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 Published on 10/15/2026 at 06:40 am EDT
Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children
Vertex Pharmaceuticals said Friday that new interim data from an open-label extension study evaluating Alyftrek in cystic fibrosis showed that some pediatric patients aged 2 to 5 years recovered... Vertex Pharmaceuticals Says Alyftrek…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com16
-
fool.com5
-
theglobeandmail.com4
-
gurufocus.com2
-
quiverquant.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 41 articles, not a forecast.